Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.

Cancer letters - 28 Aug 2017

Zhao Xiao, Wang Xiuchao, Fang Lijun, Lan Chungen, Zheng Xiaowei, Wang Yongwei, Zhang Yinlong, Han Xuexiang, Liu Shaoli, Cheng Keman, Zhao Ying, Shi Jian, Guo Jiayi, Hao Jihui, Ren He, Nie Guangjun

Abstract excerpt

KRAS mutation is the most common genetic event in pancreatic cancer. Whereas KRAS itself has proven difficult to inhibit, agents that target key downstream signals of KRAS, such as RAF, are possibly effective for pancreatic cancer treatment. Because selective BRAF inhibitors paradoxically induce downstream signaling activation, a pan-RAF inhibitor, LY3009120 is a better alternate for KRAS-mutant tumor treatment....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Phenylurea Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Porphyrins

Share to raf Kinases

Share to Tissue Array Analysis

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Share to YAP-Signaling Proteins

Source

Identifiers

PMID: 28576749
DOI: 10.1016/j.canlet.2017.05.015

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.PMID 28576749Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.Semantic proximity Read ↗

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Semantic proximity Read ↗

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.Semantic proximity Read ↗

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersSemantic proximity Read ↗

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.Semantic proximity Read ↗

Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer.Semantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic CancerSemantic proximity Read ↗

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.